(Q38063583)

28 August 2017

1 reference

title

Achieving graft-versus-tumor effect in brain tumor patients: from autologous progenitor cell transplant to active immunotherapy (English)

1 reference

28 August 2017

1 reference

1 reference

3

Hillard M Lazarus

1 reference

28 August 2017

Agne Petrosiute

1

1 reference

28 August 2017

Jeffery J Auletta

series ordinal

2

1 reference

28 August 2017

publication date

1 November 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

4

1 reference

28 August 2017

issue

11

1 reference

28 August 2017

page(s)

1139-1151

1 reference

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

28 August 2017

cites work

1 reference

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

The role of microglia in central nervous system immunity and glioma immunology

21 January 2018

1 reference

Microglia in brain tumors

21 January 2018

1 reference

A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma.

21 January 2018

1 reference

CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs).

21 January 2018

1 reference

The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses

21 January 2018

1 reference

New perspectives in glioma immunotherapy.

21 January 2018

1 reference

WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?

21 January 2018

1 reference

Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain

21 January 2018

1 reference

Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity.

21 January 2018

1 reference

Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy

21 January 2018

1 reference

Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment

21 January 2018

1 reference

Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism

21 January 2018

1 reference

T-cell apoptosis in human glioblastoma multiforme: implications for immunotherapy.

21 January 2018

1 reference

Glioma-associated cancer-initiating cells induce immunosuppression

21 January 2018

1 reference

CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo

21 January 2018

1 reference

The brain tumor microenvironment.

21 January 2018

1 reference

Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells

21 January 2018

1 reference

Transient T cell depletion causes regression of melanoma metastases

21 January 2018

1 reference

Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all.

21 January 2018

1 reference

Immunogenic anti-cancer chemotherapy as an emerging concept

21 January 2018

1 reference

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

21 January 2018

1 reference

Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy

21 January 2018

1 reference

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

21 January 2018

1 reference

Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity.

21 January 2018

1 reference

Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors

21 January 2018

1 reference

A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors.

21 January 2018

1 reference

Application of stem cell transplant for brain tumors.

21 January 2018

1 reference

High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults.

21 January 2018

1 reference

Is there a role for myeloablative chemotherapy with autologous hematopoietic cell rescue in the management of childhood high-grade astrocytomas?

21 January 2018

1 reference

Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group

21 January 2018

1 reference

Cytotoxic chemotherapy preceding apheresis of peripheral blood progenitor cells can affect the early reconstitution phase of naive T cells after autologous transplantation

21 January 2018

1 reference

Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected

21 January 2018

1 reference

A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation

21 January 2018

1 reference

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

21 January 2018

1 reference

Interleukin 15: biology and relevance to human disease

21 January 2018

1 reference

Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas

21 January 2018

1 reference

Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15.

21 January 2018

1 reference

Stem and progenitor cell-mediated tumor selective gene therapy

21 January 2018

1 reference

NK cell receptors as tools in cancer immunotherapy.

21 January 2018

1 reference

Innate or adaptive immunity? The example of natural killer cells

21 January 2018

1 reference

Effector and regulatory events during natural killer-dendritic cell interactions

21 January 2018

1 reference

Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity.

21 January 2018

1 reference

Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity

21 January 2018

1 reference

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

21 January 2018

1 reference

Targeted cellular therapy with natural killer cells

21 January 2018

1 reference

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

21 January 2018

1 reference

Regression of experimental medulloblastoma following transfer of HER2-specific T cells

21 January 2018

1 reference

Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity

21 January 2018

1 reference

New directions in natural killer cell-based immunotherapy of human cancer

21 January 2018

1 reference

Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy

21 January 2018

1 reference

Adoptive cellular immunotherapy for the treatment of malignant gliomas

21 January 2018

1 reference

Immunotherapy for glioma: getting closer to the clinical arena?

21 January 2018

1 reference

Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma

21 January 2018

1 reference

Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells

21 January 2018

1 reference

Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics

21 January 2018

1 reference

Cellular immunotherapy for high-grade glioma

21 January 2018

1 reference

HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors

21 January 2018

1 reference

Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.

21 January 2018

1 reference

Genetically engineered T cells to target EGFRvIII expressing glioblastoma

21 January 2018

1 reference

Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions

21 January 2018

1 reference

Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy.

21 January 2018

1 reference

Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas

21 January 2018

1 reference

Stem cells as therapeutic vehicles for the treatment of high-grade gliomas

21 January 2018

1 reference

Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy.

21 January 2018

1 reference

Applications of neural and mesenchymal stem cells in the treatment of gliomas

21 January 2018

1 reference

Mesenchymal stem cells: a new promise in anticancer therapy

21 January 2018

1 reference

Dendritic cell vaccines for brain tumors

21 January 2018

1 reference

Dendritic cell-based immunotherapy for malignant gliomas

21 January 2018

1 reference

Dendritic cell-based active specific immunotherapy for malignant glioma

21 January 2018

1 reference

Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study

21 January 2018

1 reference

Dendritic cell immunotherapy for malignant gliomas

21 January 2018

1 reference

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

21 January 2018

1 reference

Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors.

21 January 2018

1 reference

Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma

21 January 2018

1 reference

Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas

21 January 2018

1 reference

Treatment of recurrent metastatic medulloblastoma with intensive chemotherapy and allogeneic bone marrow transplantation.

21 January 2018

1 reference

The molecular classification of medulloblastoma: driving the next generation clinical trials

21 January 2018

1 reference

Immunotherapy targeting glioma stem cells--insights and perspectives

21 January 2018

1 reference

Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-s

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.12.96

1 reference

28 August 2017

1 reference